Lilly Recalls One Lot of Glucagon
The diabetes therapy is being recalled because of a lack of potency.
Eli Lilly is recalling one lot of Glucagon Emergency Kit for low blood sugar because of a loss of potency. Lilly has received a report saying the vial of Glucagon was in liquid form instead of the powder form. Lilly officials said in a statement that the liquid in this Glucagon vial could be related to the manufacturing process. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.
Glucagon Emergency Kit is used as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
The product is packaged in a kit containing 1 mg of freeze-dried product in a 3 mL vial and a pre-filled diluent syringe. The affected Glucagon Emergency Kit lot is D239382D and the expiration date is April 2022. The lot number can be found on the label of the kit as well as the vial. The lot was distributed nationwide to wholesalers and retailers.
Glucagon product shot
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 1st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
